User login
Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.
Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.
Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.
Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.
Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006
Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.
Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.
Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.
Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.
Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006
Key clinical point: Palbociclib plus endocrine therapy (ET) demonstrated no survival benefit over capecitabine in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (BC) who progressed on prior aromatase inhibitor (AI) therapy.
Major finding: The median overall survival was not significantly different between the palbociclib+ET and capecitabine groups in the overall population (adjusted hazard ratio [aHR] 1.00; P = .995) and the wild-type estrogen receptor-1 population (aHR 1.06; P = .683). No new safety signals were identified.
Study details: Findings are from the phase 3 PEARL study including 601 postmenopausal women with HR+/HER2− metastatic BC who progressed on prior AI therapy and were randomly assigned to receive capecitabine or palbociclib+ET with exemestane or fulvestrant.
Disclosures: This study was supported by Pfizer Inc. and AstraZeneca. Two authors declared being employees and having stock options in Pfizer, and the other authors reported ties with several sources, including Pfizer and AstraZeneca.
Source: Martin M et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12-24 (Apr 14). Doi: 10.1016/j.ejca.2022.03.006